✦ LIBER ✦

Re: Risk Factors for the Failure of Antimuscarinic Treatment with Solifenacin in Women with Overactive Bladder

✍ Scribed by Wein, Alan J.

Book ID: 122268342
Publisher: Lippincott Williams and Wilkins
Year: 2014
Tongue: English
Weight: 81 KB
Volume: 191
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2014.03.068

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk Factors for the Failure of Antimusc

Risk Factors for the Failure of Antimuscarinic Treatment With Solifenacin in Women With Overactive Bladder

✍ Serati, Maurizio; Braga, Andrea; Siesto, Gabriele; Sorice, Paola; Cattoni, Elena 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 88 KB

RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROL

RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF THE ONCE DAILY ANTIMUSCARINIC AGENT SOLIFENACIN SUCCINATE IN PATIENTS WITH OVERACTIVE BLADDER

✍ CARDOZO, L.; LISEC, M.; MILLARD, R.; van VIERSSEN TRIP, O.; KUZMIN, I.; DROGENDI 📂 Article 📅 2004 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 793 KB

782 The effect of solifenacin on bladder

782 The effect of solifenacin on bladder wall thickness in women with overactive bladder and detrusor overactivity: Results from the SHRINK study

✍ Robinson, D.; Oelke, M.; Tretter, R.; Stow, B.; Compion, G.; Tubaro, A. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 117 KB

Cost-Effectiveness of Mirabegron Compare

Cost-Effectiveness of Mirabegron Compared with Antimuscarinics for the Treatment of Patients with Overactive Bladder in the United Kingdom

✍ Maman, K.; Neine, M.; Briquet, B.; Nazir, J.; Odeyemi, I.A.O.; Hakimi, Z.; Garnh 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

Randomized, double-blind placebo- and to

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

✍ C.R. Chapple; T. Rechberger; S. Al-Shukri; P. Meffan; K. Everaert; M. Huang; A. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB

Randomized, double-blind, placebo- and p

Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder

✍ Osamu Yamaguchi; Eiji Marui; Hidehiro Kakizaki; Naoki Itoh; Takashi Yokota; Hiro 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB